CRIS Current Research Information System

STEFANINI, BERNARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.540
NA - Nord America 1.836
EU - Europa 1.158
SA - Sud America 190
Continente sconosciuto - Info sul continente non disponibili 181
AF - Africa 109
OC - Oceania 2
Totale 7.016
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.734
VN - Vietnam 929
CN - Cina 885
SG - Singapore 766
IT - Italia 590
BD - Bangladesh 324
HK - Hong Kong 197
KR - Corea 161
BR - Brasile 130
NL - Olanda 109
DE - Germania 86
IN - India 75
FR - Francia 69
JP - Giappone 62
FI - Finlandia 60
CA - Canada 45
SE - Svezia 44
GB - Regno Unito 36
ZA - Sudafrica 34
IE - Irlanda 32
RU - Federazione Russa 30
AT - Austria 24
MX - Messico 23
SC - Seychelles 23
AR - Argentina 22
TH - Thailandia 22
PH - Filippine 21
CH - Svizzera 15
TW - Taiwan 15
PK - Pakistan 13
PL - Polonia 12
BG - Bulgaria 11
CI - Costa d'Avorio 11
ID - Indonesia 11
IQ - Iraq 11
TR - Turchia 11
CO - Colombia 9
JM - Giamaica 9
MA - Marocco 9
CR - Costa Rica 7
EC - Ecuador 7
CL - Cile 6
EG - Egitto 6
ES - Italia 6
MY - Malesia 6
UA - Ucraina 6
VE - Venezuela 6
BE - Belgio 5
HN - Honduras 5
RO - Romania 5
TG - Togo 5
AZ - Azerbaigian 4
DZ - Algeria 4
LT - Lituania 4
NG - Nigeria 4
PY - Paraguay 4
UZ - Uzbekistan 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
IL - Israele 3
KE - Kenya 3
LB - Libano 3
PR - Porto Rico 3
SA - Arabia Saudita 3
SV - El Salvador 3
AE - Emirati Arabi Uniti 2
BF - Burkina Faso 2
CZ - Repubblica Ceca 2
JO - Giordania 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BT - Bhutan 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MF - Saint Martin 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 6.832
Salva come PNG Salva come JPEG
Città #
Singapore 507
Hefei 330
Ashburn 263
Hanoi 250
San Jose 249
Ho Chi Minh City 245
Hong Kong 172
Bologna 168
Seoul 143
Council Bluffs 105
New York 90
Santa Clara 87
Los Angeles 79
Boardman 65
Beijing 64
Tokyo 52
Dallas 51
Da Nang 49
Milan 48
Rome 48
Buffalo 42
Lauterbourg 42
Bengaluru 34
Johannesburg 33
Dublin 32
Haiphong 29
Helsinki 29
Lappeenranta 29
Frankfurt am Main 28
São Paulo 27
Amsterdam 25
Naples 21
Guangzhou 20
Palermo 20
Chicago 17
Nuremberg 17
Orem 17
Redondo Beach 17
Can Tho 15
Montreal 14
Tongling 14
Vienna 14
Falkenstein 13
Mexico City 12
Abidjan 11
Bern 11
Denver 11
Florence 11
Ninh Bình 11
Shanghai 11
Sofia 11
Toronto 11
Warsaw 11
Brooklyn 10
Munich 10
Shenzhen 10
Stockholm 10
The Dalles 10
Turin 10
Atlanta 9
Biên Hòa 9
Lahore 9
Phoenix 9
Vĩnh Long 9
Chandler 8
Genoa 8
Ha Long 8
Houston 8
Hải Dương 8
Jakarta 8
Baghdad 7
Bangkok 7
Charlotte 7
Chennai 7
Modena 7
San Francisco 7
Thái Nguyên 7
Boston 6
Bắc Ninh 6
Philadelphia 6
Quận Ba 6
Rimini 6
San José 6
Seattle 6
Shenyang 6
St Petersburg 6
Venice 6
Vũng Tàu 6
Bucharest 5
Curitiba 5
Hưng Yên 5
Lomé 5
Nha Trang 5
Parma 5
Phú Thọ 5
Quận Một 5
Salt Lake City 5
San Diego 5
Shijiazhuang 5
Tân Tiến 5
Totale 4.053
Salva come PNG Salva come JPEG
Nome #
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 246
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 229
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 214
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 202
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 196
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 194
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 191
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 189
Association between anatomic variations of extrahepatic and intrahepatic bile ducts: Do look up! 184
TKIs in combination with immunotherapy for hepatocellular carcinoma 166
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 163
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 161
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 159
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 152
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 152
Advancements in immunotherapy for hepatocellular carcinoma 149
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease 142
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 141
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 122
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe 120
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 119
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 116
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 112
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 111
Artificial intelligence in Ultrasound: Pearls and pitfalls in 2024 111
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 104
Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review 104
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 104
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 104
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 103
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma 100
RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives 96
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 96
Thinking outside the box: unconventional artificial intelligence algorithms in the detection and management of liver cirrhosis 94
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 94
HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients 91
Conversion to liver transplantation following atezolizumab-bevacizumab for HCC: the Bologna experience 91
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement 87
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 86
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? 85
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 84
Liver Fat Quantification: When do We Need It? 82
Letter to the editor on the article Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement by Zhou and collaborators 81
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 81
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 81
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 78
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 78
OS-064 Integrating gut microbiota composition and machine learning to predict therapeutic response in hepatocellular carcinoma treated with Atezolizumab and Bevacizumab: exploratory analysis from the phase 3b AMETHISTA study 76
Perirenal ultrasound abnormality: When to think at Xantogranulomatous Erdheim-Chester disease 76
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma 74
Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease 73
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib 72
Ultrasound, the handyman serving our whole populations in the post COVID-19 pandemic 72
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials 64
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause? 59
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis? 58
Occupational toxicants in MASLD: Bias, complexity, and future directions 53
THU-402-YI Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in noncirrhotic MASLD patients 52
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 50
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 48
THU-401 Liver stiffness and MACE development: an intricate relationship 47
Ultrasound in clinical enviroments: Where are we standing? 46
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 41
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab 10
Totale 7.016
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.536
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.536
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 0 0 1 7 2 0 2 4
2022/2023130 2 9 5 4 6 8 5 10 36 3 20 22
2023/2024166 10 14 12 11 12 30 7 28 10 12 12 8
2024/20251.104 24 78 76 73 102 46 103 32 47 106 122 295
2025/20265.197 375 444 284 375 434 167 605 274 922 379 500 438
2026/2027403 164 239 0 0 0 0 0 0 0 0 0 0
Totale 7.016